These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2007-004981-42||Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.||bad-data|
|Ongoing||2014-001270-33||A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel, i...||not-yet-due|
|Ongoing||2016-000171-24||Phase II study of gemcitabine, carboplatin and VELIPARIB (ABT-888) in refractory testicular germ cell cancer.||not-yet-due|
|Not reported||2016-004632-38||Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer.||2019-05-13||due-trials|
|Ongoing||2019-000558-68||Phase II study of disulfiram and cisplatin in refractory testicular germ cell cancer.||not-yet-due|
|Ongoing||2019-001957-16||Phase II study of Vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic breast cancer.||not-yet-due|